Lilly Axes Axid: Reliant Assumes U.S. Sales And Marketing Rights
Executive Summary
Reliant Pharmaceuticals' second adopted brand is the Lilly H2 antagonist Axid (nizatidine), a product with current annual sales of about $200 mil.
You may also be interested in...
Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees
Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions
Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees
Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions
Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild
A successor to the anti-epileptic Felbatol is among the development projects for Carter-Wallace's healthcare unit following its acquisition by an investment firm run by former Warner-Lambert exec Anthony Wild.